EVALUATION OF EVALUATION OF RA & PA RA & PA

PATIENTSPATIENTS

YEAR 2005YEAR 2005

GENERAL DEMOGRAPHICSGENERAL DEMOGRAPHICSGENDERGENDER

♀ ♀ %% ♂♂ %% Total Total

RARA 313313 75,2475,24 103103 24,7624,76 416416

PAPA 120120 58,8258,82 8484 40,1840,18 204204

ASAS 147147 35,3335,33 269269 64,6764,67 416416

TotalTotal 580580 55,9855,98 456456 44,0244,02 10361036

PATIENTS’ AGE GROUPSPATIENTS’ AGE GROUPS

-20-20 %%21-21-4040 %%

41-41-6060 %% 61+61+ %% Mean Mean

RARA 22 0,480,48 4848 11,5311,53 222222 53,3653,36 144144 34,6134,61 54,7154,71

PAPA 00 00 2626 12,7412,74 132132 64,7064,70 4646 22,5422,54 53,1653,16

ASAS 00 00 8080 19,219,2 281281 67,567,5 5555 13,313,3 49,749,7

Total Total 22 0,190,19 154154 14,8614,86 635635 61,2961,29 245245 23,6423,64 52,452,4

DURATION OF DISEASE AGEDURATION OF DISEASE AGE

-10-10 %%11-11-2020 %%

21-21-3030 %% 31+31+ %% MeanMean

RARA 188188 45,1945,19 143143 34,3734,37 5353 12,7412,74 3232 7,697,69 14,1714,17

PAPA 7878 38,2338,23 9191 44,644,6 2222 10,7810,78 1313 6,376,37 14,0814,08

ASAS 122122 29,329,3 156156 37,537,5 101101 24,324,3 3737 8,98,9 16,916,9

Total Total 388388 37,4537,45 390390 37,6437,64 176176 16,9816,98 8282 7,917,91 15,2515,25

DIFFERENCE OF MS DIFFERENCE OF MS AT POSTTREATMENTAT POSTTREATMENT

MS1MS1

--

MS2MS2

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 512512 82,5882,58 1313 2,092,09 9595 15,3215,32

MEANMEAN MS1MS1 MS2MS2

RA-PARA-PA 54,4154,41 20,6620,66

DIFFERENCE OF VAS (PAIN)DIFFERENCE OF VAS (PAIN)AT POSTTREATMENTAT POSTTREATMENT

VAS1VAS1

--

VAS2VAS2

(pain)(pain)

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 573573 92,4192,41 4040 6,456,45 77 1,121,12

MEANMEAN VAS1VAS1 VAS2VAS2

RA-PARA-PA 47,9347,93 18,118,1

DIFFERENCE OF OWB DIFFERENCE OF OWB AT POSTTREATMENTAT POSTTREATMENT

OWB1OWB1

--

OWB2OWB2

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 575575 92,7492,74 3434 5,485,48 1111 1,771,77

MEANMEAN OWB1OWB1 OWB2OWB2

RA-PARA-PA 51,1851,18 19,0519,05

DIFFERENCE OF MHAQ DIFFERENCE OF MHAQ AT POSTTREATMENTAT POSTTREATMENT

MHAQ1MHAQ1

--

MHAQ2MHAQ2Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 506506 81,6181,61 3131 55 8383 13,3813,38

MEANMEAN MHAQ1MHAQ1 MHAQ2MHAQ2

RA-PARA-PA 16,1116,11 12,3512,35

DIFFERENCE OF PaGADA DIFFERENCE OF PaGADA AT POSTTREATMENTAT POSTTREATMENT

PaGADA1PaGADA1

--

PaGADA2PaGADA2

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 563563 90,890,8 4545 7,257,25 1212 1,931,93

MEANMEAN PaGADA1PaGADA1 PaGADA2PaGADA2

RA-PARA-PA 47,5147,51 19,2219,22

DIFFERENCE OF TJ DIFFERENCE OF TJ AT POSTTREATMENTAT POSTTREATMENT

TJ1TJ1

--

TJ2TJ2Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 556556 89,6789,67 1212 1,931,93 5252 8,388,38

MEANMEAN TJ1TJ1 TJ2TJ2

RA-PARA-PA 8,748,74 2,242,24

DIFFERENCE OF SwJ DIFFERENCE OF SwJ AT POSTTREATMENTAT POSTTREATMENT

SwJ1SwJ1

--

SwJ2SwJ2

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 9090 14,5114,51 1515 2,412,41 515515 83,0683,06

MEANMEAN SwJ1SwJ1 SwJ2SwJ2

RA-PARA-PA 0,750,75 0,290,29

DIFFERENCE OF PGADA DIFFERENCE OF PGADA AT POSTTREATMENTAT POSTTREATMENT

PGADA1PGADA1

--

PGADA2PGADA2

Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 598598 96,4596,45 1010 1,611,61 1212 1,931,93

MEANMEAN PGADA1PGADA1 PGADA2PGADA2

RA-PARA-PA 42,4842,48 14,9314,93

DIFFERENCE OF DAS 28DIFFERENCE OF DAS 28AT POSTTREATMENTAT POSTTREATMENT

DAS-28 1DAS-28 1

--

DAS-28 2DAS-28 2Dec Dec %% IncInc %% SameSame %%

RA-PARA-PA 601601 96,9396,93 99 1,451,45 1010 1,611,61

MEANMEAN DAS-28 1DAS-28 1 DAS-28 2DAS-28 2

RA-PARA-PA 2,182,18 0,830,83

ANALGESIC USAGE ANALGESIC USAGE AT PRETREATMENTAT PRETREATMENT

AA A-A- %% A+A+ %%

RA-PARA-PA 413413 66,6166,61 207207 33,3833,38

DIFFERENCE OF “A” USAGE AT DIFFERENCE OF “A” USAGE AT POSTTREATMENTPOSTTREATMENT

AA SameSame %% Dec Dec %% IncInc %% Sep Sep %%

RA-RA-PAPA

8989 42,9942,99 7171 34,2934,29 88 3,863,86 3939 18,8418,84

NSAID USAGE NSAID USAGE AT PRETREATMENTAT PRETREATMENT

NSAIDNSAID NSAID-NSAID- %% NSAID+NSAID+ %%

RA-PARA-PA 253253 40,8040,80 367367 59,1959,19

DIFFERENCE OF NSAID USAGE DIFFERENCE OF NSAID USAGE AT POSTTREATMENTAT POSTTREATMENT

NSNS

AIDAID

SameSame %% Dec Dec %% IncInc %% Sep Sep %%

RA-RA-PAPA

243243 66,2166,21 6464 17,4317,43 77 1,91,9 5353 14,4414,44

STEROID USAGE STEROID USAGE AT PRETREATMENTAT PRETREATMENT

STRSTR STR-STR- %% STR+STR+ %%

RA-PARA-PA 484484 78,0678,06 136136 21,9321,93

DIFFERENCE OF “STR” USAGE DIFFERENCE OF “STR” USAGE AT POSTTREATMENTAT POSTTREATMENT

STRSTR SameSame %% Dec Dec %% IncInc %% Sep Sep %%

RA-RA-PAPA

110110 80,8880,88 1414 10,2910,29 44 2,942,94 88 5,885,88

USAGE OF OTHER DRUGS USAGE OF OTHER DRUGS AT PRETREATMENTAT PRETREATMENT

OTHOTH OTHER-OTHER- %% OTHER+OTHER+ %%

RA-PARA-PA 228228 36,7736,77 392392 63,2263,22

DIFFERENCE OF OTHER DRUGS DIFFERENCE OF OTHER DRUGS AT POSTTREATMENTAT POSTTREATMENT

OTHOTH SameSame %% Dec Dec %% IncInc %% Sep Sep %%

RA-RA-PAPA 372372 94,8994,89 99 2,292,29 33 0,760,76 88 2,042,04

MOSTLY SEEN MOSTLY SEEN SECONDARY DISEASESSECONDARY DISEASES

SEC.SEC.

DIS.DIS.

NONO

%%

YESYES

%%

HTHT

%%

CADCAD

%%

DMDM

%%COLDCOLD

%%

CACA

%%DEPRDEPR

%%

TROITROI

%%

OTHOTH

%%

RA-RA-PAPA

272272

43,8743,87

348348

56,1256,12

9494

27,0127,01

3939

11,211,2

2424

6,896,89

3333

9,489,48

1010

2,872,87

1616

4,594,59

5656

16,0916,09

180180

51,7251,72

DAILY POLICLINIC CASESDAILY POLICLINIC CASES

PCPC NONO

%%

YESYES

%%

TRATRA

%%

EYEEYE

%%

URSURS

%%

DERDER

%%

DIARDIAR

%%

PAINPAIN

%%

USEUSE

%%

OTHOTH

%%

RA-RA-PAPA

410410

66,1266,12

210210

33,8733,87

77

3,333,33

44

1,91,9

3737

17,6117,61

1212

5,715,71

1313

6,196,19

120120

57,1457,14

1010

4,764,76

2323

10,9510,95

PATIENTS WHO WERE PATIENTS WHO WERE REFERRED TO HOSPITALREFERRED TO HOSPITAL

CONCONSULTSULT

NONO

%%

MRMR

%%

EYEEYE

%%

ENTENT

%%

DERDER

%%

RHERHE

%%

ORTORT

%%

NEUNEU

%%

RA-RA-PAPA

605605

97,5897,58

44

0,640,64

33

0,480,48

33

0,480,48

11

0,160,16

22

0,320,32

11

0,160,16

11

0,160,16

THANK YOUTHANK YOU

FOR YOUR ATTENTIONFOR YOUR ATTENTION